2 recruiting, 1 not yet recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow Lei ZHAO: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular SBRT, Sintilimab, Surgery - HCC | Phase 2 | Not yet recruiting | Lei ZHAO | 110 | 2025-12-28 | 2026-01-20 |
| Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC HAIC, Adebrelimab, Apatinib - Intrahepatic Cholangiocarcinoma | Phase 2 | Recruiting | Lei ZHAO | 20 | 2024-03-01 | 2024-04-17 |
| Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC HAIC, Sintilimab, Lenvatinib - HCC | Phase 2 | Recruiting | Lei ZHAO | 40 | 2023-10-25 | 2025-04-01 |
Surgical Procedures, Operative (2) · sintilimab (2) · apatinib (1) · lenvatinib (1)
China (3)